journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Medical Oncology

journal
https://read.qxmd.com/read/30719102/the-impact-of-the-glasgow-prognostic-score-on-survival-in-second-line-chemotherapy-for-metastatic-colorectal-cancer-patients-with-braf-v600e-mutation
#1
Seiichiro Mitani, Hiroya Taniguchi, Keiji Sugiyama, Toshiki Masuishi, Kazunori Honda, Yukiya Narita, Shigenori Kadowaki, Takashi Ura, Masashi Ando, Masahiro Tajika, Yasushi Yatabe, Kei Muro
Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival. Recently, clinical trials have been conducted to improve outcomes of second or later lines of chemotherapy. However, there is a paucity of reference data pertaining to outcomes of second-line chemotherapy and prognostic factors that are relevant only to BRAF mutant patients. Patients and methods: We retrospectively reviewed metastatic colorectal cancer patients with BRAF V600E mutation who underwent second-line chemotherapy between January 2007 and March 2017...
2019: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30671144/academic-oncology-clinicians-understanding-of-biosimilars-and-information-needed-before-prescribing
#2
John W Cook, Megan K McGrath, Margie D Dixon, Jeffrey M Switchenko, R Donald Harvey, Rebecca D Pentz
Background: With increasing numbers of oncology biosimilars in the approval pipeline, it is important to investigate oncology clinicians' understanding of biosimilars and what information they need prior to adoption. Methods: Between January and May 2018, 77 oncology clinicians (52 physicians, 16 pharmacists, and 9 advanced practice providers) completed a survey covering three domains: clinician understanding, prescription preferences, and patient involvement. An in-depth interview was designed based on themes identified in the first 50 surveys: cost, safety and efficacy, patient preference, and disease stage...
2019: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30643582/clinically-relevant-drug-interactions-with-multikinase-inhibitors-a-review
#3
REVIEW
Koen G A M Hussaarts, G D Marijn Veerman, Frank G A Jansman, Teun van Gelder, Ron H J Mathijssen, Roelof W F van Leeuwen
Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. Although the oral route of administration offers improved flexibility and convenience for the patient, challenges arise in the use of MKIs. As MKIs are prescribed extensively, patients are at increased risk for (severe) drug-drug interactions (DDIs). As a result of these DDIs, plasma pharmacokinetics of MKIs may vary significantly, thereby leading to high interpatient variability and subsequent risk for increased toxicity or a diminished therapeutic outcome...
2019: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30636977/predicting-mortality-and-adverse-events-in-patients-with-advanced-pancreatic-cancer-treated-with-palliative-gemcitabine-based-chemotherapy-in-a-multicentre-phase-iii-randomized-clinical-trial-the-apc-sakk-risk-scores
#4
Piera Gargiulo, Daniel Dietrich, Richard Herrmann, György Bodoky, Thomas Ruhstaller, Werner Scheithauer, Bengt Glimelius, Simona Berardi, Sandro Pignata, Peter Brauchli
Background: The prognosis of advanced pancreatic cancer (APC) is poor and differs considerably among patients. Therefore, it is clinically relevant to identify patients with APC who are more likely to benefit from palliative chemotherapy with reduced risk of toxicity. To date, there is no prognostic score universally recommended to help clinicians in planning the therapeutic management. Methods: Using individual patient data from 319 cases of APC treated with gemcitabine-based chemotherapy and enrolled in the SAKK 44/00-CECOG/PAN...
2019: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30622654/cancer-stem-cells-in-hepatocellular-carcinoma-an-overview-and-promising-therapeutic-strategies
#5
REVIEW
Nuozhou Wang, Shanshan Wang, Ming-Yue Li, Bao-Guang Hu, Li-Ping Liu, Sheng-Li Yang, Shucai Yang, Zhongqin Gong, Paul B S Lai, George G Chen
The poor clinical outcome of hepatocellular carcinoma (HCC) patients is ascribed to the resistance of HCC cells to traditional treatments and tumor recurrence after curative therapies. Cancer stem cells (CSCs) have been identified as a small subset of cancer cells which have high capacity for self-renewal, differentiation and tumorigenesis. Recent advances in the field of liver CSCs (LCSCs) have enabled the identification of CSC surface markers and the isolation of CSC subpopulations from HCC cells. Given their central role in cancer initiation, metastasis, recurrence and therapeutic resistance, LCSCs constitute a therapeutic opportunity to achieve cure and prevent relapse of HCC...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30619511/cdk4-6-inhibitors-in-breast-cancer-beyond-hormone-receptor-positive-her2-negative-disease
#6
REVIEW
Adriana Matutino, Carla Amaro, Sunil Verma
The development of cyclin-dependent kinase (CDK) 4/6 inhibitors has been more prominent in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancers, with a significant improvement in progression-free survival (PFS) in first and later lines of metastatic breast cancer (MBC) therapy. Preclinical evidence suggests that there is activity of CDK4/6 inhibitors in nonluminal cell lines. Here, we present a review of the current preclinical and clinical data on the use of CDK inhibitors in HER2-positive and triple-negative breast cancer (TNBC)...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30574212/immunotherapy-and-pancreatic-cancer-unique-challenges-and-potential-opportunities
#7
REVIEW
Kate Young, Daniel J Hughes, David Cunningham, Naureen Starling
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over 300,000 deaths per year globally there is an urgent unmet need to improve the therapeutic options available. Novel immunotherapies have shown promising results across multiple solid tumours, in a number of cases surpassing chemotherapy as a first-line therapeutic option. However, to date, trials of single-agent immunotherapies in PDAC have been disappointing and PDAC has been labelled as a nonimmunogenic cancer...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30574211/gene-code-cd274-pd-l1-from-molecular-basis-toward-cancer-immunotherapy
#8
REVIEW
Federico Pio Fabrizio, Domenico Trombetta, Antonio Rossi, Angelo Sparaneo, Stefano Castellana, Lucia Anna Muscarella
The programmed death 1 receptor (PD-1) and its ligand (PD-L1) are key molecules of immune checkpoint mechanisms in cancer and actually represent one of the main targets of immunotherapy. The predictive and prognostic values of PD-L1 expression alone in cancer patients is currently under debate due to the methodological assessment of PD-L1 expression and its temporal variations. Better detailed studies about the molecular basis of immunotherapy biomarkers are necessary. Here we summarize the current knowledge of PD-L1 gene modifications at genetic and epigenetic levels in different tumors, thus highlighting their reported correlation with cellular processes and potential impact on patient outcomes...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30574210/managing-advanced-hr-positive-her2-negative-breast-cancer-with-cdk4-6-inhibitors-in-post-menopausal-patients-is-there-a-best-sequence
#9
EDITORIAL
Lorenzo Rossi, Amelia McCartney, Emanuela Risi, Luca Malorni, Laura Biganzoli, Angelo Di Leo
The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinase 4/6 (CDK4/6). In the context of CDK4/6 inhibitors, landmark clinical trials for palbociclib (PALOMA-1, PALOMA-2, PALOMA-3), ribociclib (MONALEESA-2, MONALEESA-3, MONALEESA-7) and abemaciclib (MONARCH-1, MONARCH-2, MONARCH-3) have provided solid data regarding progression-free survival and overall response rate, justifying the introduction of this class of drugs into our therapeutic armoury...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30574209/corrigendum
#10
(no author information available yet)
[This corrects the article DOI: 10.1177/1758835918793849.].
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30574208/corrigendum
#11
(no author information available yet)
[This corrects the article DOI: 10.1177/1758835918793326.].
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30542378/inhibitors-targeting-cdk4-6-parp-and-pi3k-in-breast-cancer-a-review
#12
REVIEW
Siti Muhamad Nur Husna, Hern-Tze Tina Tan, Rohimah Mohamud, Anne Dyhl-Polk, Kah Keng Wong
Breast cancer is the global leading cause of cancer-related death in women and it represents a major health burden worldwide. One of the promising breast cancer therapeutic avenues is through small molecule inhibitors (SMIs) which have undergone rapid progress with successful clinical trials. Recently, three emerging and vital groups of proteins are targeted by SMIs for breast cancer treatment, namely cyclin-dependent kinase 4 and 6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP) and phosphoinositide 3-kinase (PI3K)...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30542377/phase-ib-ii-single-arm-trial-evaluating-the-combination-of-everolimus-lapatinib-and-capecitabine-for-the-treatment-of-her2-positive-breast-cancer-with-brain-metastases-trio-us-b-09
#13
Sara Hurvitz, Rashi Singh, Brad Adams, Julie A Taguchi, David Chan, Robert A Dichmann, Aurelio Castrellon, Eddie Hu, Jonathan Berkowitz, Aruna Mani, Brian DiCarlo, Rena Callahan, Ira Smalberg, Xiaoyan Wang, Ivana Meglar, Diego Martinez, Evthokia Hobbs, Dennis J Slamon
Background: Improving outcomes for patients with human epidermal growth factor 2-positive (HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This trial evaluated a novel combination of everolimus, lapatinib and capecitabine for this disease. Methods: Patients with trastuzumab-pretreated, HER2+ breast cancer brain metastasis without prior therapy with a mammalian target of rapamycin (mTOR) inhibitor were eligible. Patients received lapatinib and everolimus daily (continuously) and capecitabine twice daily (d1-14) in 21-d cycles...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30479672/assessing-response-to-neo-adjuvant-therapy-in-locally-advanced-rectal-cancer-using-intra-voxel-incoherent-motion-modelling-by-dwi-data-and-standardized-index-of-shape-from-dce-mri
#14
Antonella Petrillo, Roberta Fusco, Vincenza Granata, Salvatore Filice, Mario Sansone, Daniela Rega, Paolo Delrio, Francesco Bianco, Giovanni Maria Romano, Fabiana Tatangelo, Antonio Avallone, Biagio Pecori
Background: Our aim was to investigate preoperative chemoradiation therapy (pCRT) response in locally advanced rectal cancer (LARC) comparing standardized index of shape (SIS) obtained from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with intravoxel-incoherent-motion-modelling-derived parameters by diffusion-weighted imaging (DWI). Materials and methods: Eighty-eight patients with LARC were subjected to MRI before and after pCRT. Apparent diffusion coefficient (ADC), tissue diffusion (Dt ), pseudodiffusion (Dp ) and perfusion fraction (f) were calculated and percentage changes ∆ADC, ∆Dt , ∆Dp , ∆f were computed...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30479671/use-of-cyclin-dependent-kinase-4-6-cdk4-6-inhibitors-in-older-patients-with-er-positive-her2-negative-breast-cancer-young-international-society-of-geriatric-oncology-review-paper
#15
REVIEW
Nicolò Matteo Luca Battisti, Nienke De Glas, Mina S Sedrak, Kah Poh Loh, Gabor Liposits, Enrique Soto-Perez-de-Celis, Jessica L Krok-Schoen, Ines B Menjak, Alistair Ring
The current standard of care for the management of estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer has been redefined by the introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Although adults aged 65 years and older account for the majority of patients with breast cancer, limited data are available about the age-specific dosing, tolerability, and benefit of CDK4/6 inhibitors in this growing population. Older adults are under-represented in clinical trials and as a result, clinicians are forced to extrapolate from findings in younger and healthier patients when making treatment decisions for older patients...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30344651/durvalumab-in-nsclc-latest-evidence-and-clinical-potential
#16
REVIEW
Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares
Advances in immunotherapy have led to radical improvements in outcomes, including overall survival, such as in non-small cell lung cancer (NSCLC) patients with metastatic disease treated with immune checkpoint inhibitors. More recently, promising results have been obtained in earlier disease settings, and combinations with other therapies are being actively investigated. Durvalumab, a monoclonal antibody directed against the programmed death ligand 1, has demonstrated significant activity in NSCLC, including increased progression-free survival rates after chemoradiation for unresectable stage III disease, with a favourable safety profile...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30344650/-18-f-fdg-pet-ct-imaging-in-cardiac-tumors-illustrative-clinical-cases-and-review-of-the-literature
#17
Maristella Saponara, Valentina Ambrosini, Margherita Nannini, Lidia Gatto, Annalisa Astolfi, Milena Urbini, Valentina Indio, Stefano Fanti, Maria Abbondanza Pantaleo
Cardiac tumors are a very rare condition. Mostly, they are benign tumors (75%), with myxomas being the most frequent. The remaining 25% are malignant; either primary malignant sarcoma or secondary metastases. Given the small number of cases reported and the lack of prospective and randomized clinical trials, the level of evidence for the optimal multimodal treatment of primary cardiac sarcomas is very low and the optimal imaging diagnostic workup is not well established. In particular, 18 F-FDG-PET/CT is not yet included in routine diagnosis of cardiac masses...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30305851/salvage-surgery-for-recurrent-or-persistent-tumour-after-radical-chemo-radiotherapy-for-locally-advanced-non-small-cell-lung-cancer-a-systematic-review
#18
REVIEW
Chris Dickhoff, Rene H J Otten, Martijn W Heymans, Max Dahele
Background: Once recurrent or persistent locoregional tumour after radical chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) is identified, few curative-intent treatment options are available. Selected patients might benefit from surgical salvage. We performed a systematic review of the available literature for this emerging treatment option. Methods: A systematic literature search was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30302130/primary-cilium-and-glioblastoma
#19
REVIEW
María Álvarez-Satta, Ander Matheu
Glioblastoma (GBM) represents the most common, malignant and lethal primary brain tumour in adults. The primary cilium is a highly conserved and dynamic organelle that protrudes from the apical surface of virtually every type of mammalian cell. There is increasing evidence that abnormal cilia are involved in cancer progression, since primary cilia regulate cell cycle and signalling transduction. In this review, we summarize the role of primary cilium specifically with regard to GBM, where there is evidence postulating it as a critical mediator of GBM tumorigenesis and progression...
2018: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30263067/corrigendum
#20
(no author information available yet)
[This corrects the article DOI: 10.1177/1758834017741073.].
2018: Therapeutic Advances in Medical Oncology
journal
journal
42443
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"